Published 6 issues per year
ISSN Print: 1045-4403
ISSN Online: 2162-6502
Indexed in
Association of Interleukin 28B Polymorphism with Clearance of Hepatitis C Virus: A Mini Review
ABSTRACT
The highly infectious hepatitis C virus (HCV) is the major cause of chronic hepatitis around the globe. Approximately 3% of the world's population has been affected by both chronic and acute HCV. In this study, we highlight the relationship between single-nucleotide proteins (SNPs) and interleukin (IL) IL28B on chromosome 19 with the treatment response of chronic HCV infection along with its sustained virologic response (SVR). Four SNPs are strongly linked with HCV self-clearance: rs8099917 TT, rs12980275 AA, rs8105790 TT, and rs10853728 CC. Most SNPs, including rs12979860, are located upstream of the IL28B gene fragment, encoding interferon (IFN)-λ3. We find that IL28B variants rs8099917 and rs12979860 strongly influence results of combined pegylated (PEG)-IFN/ribavirin (RBV) therapy. In the case of SNP rs12979860, the CC genotype is linked with greater than a twofold higher SVR than that with TT or CT genotypes. These SNPs are associated with expression of intrahepatic IFN-stimulated genes in liver. Past research shows that females are more efficient in resolving HCV infection, regardless of IL28B genotype. Similar results of IL28B polymorphisms associated with spontaneous HCV clearance were also obtained in Chinese and Taiwanese HCV patients. Another report of RBV and PEG-IFN−treated patients revealed that age, viral load, rs8099917 genotype, and fibrosis were major predictors of antiviral therapeutic response. To select favorable antiviral regimes for treatment using IFN, a combination of host genetic data and viral genotyping may be useful in treating chronic HCV. We propose that these predictive factors must be considered before commencing treatment in HCV patients.
-
Lam N, Gotsch PB, Langan RC. Caring for pregnant women and newborns with hepatitis B or C. Am Fam Phys. 2010;82(10):1225-9.
-
Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin Liver Dis. 1995 Feb;15(1):41-63.
-
Kazemi B, Bandehpour M, Seyed N, Roozbehi M, Mosaffa N. Cloning and expression of hepatitis C virus core protein in pGemex-1 expression vector. Arch Iran Med. 2008;11(2):173-8.
-
Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE. The natural history of community-acquired hepatitis C in the United States. New Engl J Med. 1992;327(27):1899-905.
-
Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: A systematic review of prevalence, genotypes and risk factors. World J Gastroenterol. 2009;15(45):5647.
-
Timm J, Roggendorf M. Sequence diversity of hepatitis C virus: Implications for immune control and therapy. World J Gastroenterol. 2007;13(36):4808.
-
Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S; Hepatitis C Intervention Therapy Group. Pegylated interferon-a2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther. 2000 Nov;68(5):556-67.
-
Novikov BN, Grimsley JK, Kern RJ, Wild JR, Wales ME. Improved pharmacokinetics and immunogenicity profile of organophosphorus hydrolase by chemical modification with polyethylene glycol. J Control Rel. 2010;146(3):318-25.
-
Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK. A randomized, double-blind trial comparing pegylated interferon a-2b to interferon a-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34(2):395-403.
-
Mathur P, Kottilil S, Wilson E. Use of ribavirin for hepatitis C treatment in the modern direct-acting antiviral era. J Clin Transl Hepatol. 2018;6(4):431-37. doi:10.14218/ JCTH.2018.00007.
-
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M-H, Albrecht JK. PEG interferon a-2b plus ribavirin compared with interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358(9286):958-65.
-
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
-
Mangia A, Thompson A J, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139(3):821-7.e1.
-
Indolfi G, Sambrotta M, Moriondo M, Azzari C, Resti M. Genetic variation in interleukin-28B locus is associated with spontaneous clearance of HCV in children with non-1 viral genotype infection. Hepatology. 2011; 54(4):1490-1.
-
Lindh M, Lagging M, Farkkila M, Langeland N, March K, Nilsson S, Norkrans G, Pedersen C, Buhl MR, Westin J, Hellstrand K. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis. 2011;203(12):1748-52.
-
Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Li YN, Wu MS, Dai CY, Juo SH, Chuang WL. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology. 2011;53(1):7-13.
-
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798-801.
-
de Castellarnau M, Aparicio E, Parera M, Franco S, Tural C, Clotet B, Martinez MA. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-a and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS One. 2012;7(2):e31016.
-
Rao HY, Sun DG, Jiang D, Yang RF, Guo F, Wang JH, Liu F, Zhang HY, Zhang HH, Du SC, Jin Q, Qin H, Lok AS, Wei L. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat. 2012;19(3):173-81.
-
Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, Hiraga N, Kawakami Y, Aimitsu S, Kao JH, Kubo M, Tsunoda T, Kumada H, Nakamura Y, Hayes CN, Chayama K. IL-28B predicts response to chronic hepatitis C therapy-fine-mapping and replication study in Asian populations. J Gen Virol. 2011;92(Pt 5):1071-81.
-
Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology. 2010;139(6):1865-76.
-
Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010;139(2):499-509.
-
Doyle JS, Hellard ME, Thompson AJ. The role of viral and host genetics in natural history and treatment of chronic HCV infection. Best Prac Res Clin Gastroenterol. 2012;26(4):413-27.
-
Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436(7053):967-72.
-
Tillmann H, Thompson A, Patel K, Wiese M, Tenckhoff H, Nischalke H, Kullig U, Goebel U, Capka E, Wiegand J. IL28B polymorphism is associated with jaundice during acute HCV infection and is a strong predictor for spontaneous clearance in the prospective German anti-D cohort. J Hepatol. 2010;52:S56.
-
Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, Yeung B, Marks P, Rawlinson W, Lloyd AR. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52(4):1216-24.
-
Fischer J, Bohm S, Scholz M, Muller T, Witt H, George J, Sarrazin C, Susser S, Schott E, Suppiah V. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology. 2012;55(6): 1700-10.
-
Lin C-Y, Chen J-Y, Lin T-N, Jeng W-J, Huang C-H, Huang C-W, Chang S-W, Sheen I-S. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One. 2011;6(3):e18322.
-
Sticchi L, Di Biagio A, Rappazzo E, Setti M, De Rosa G, De Hoffer L, Nicolini L, Prinapori R, Bruzzone B. rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: Simultaneous genotyping in Caucasian patients infected with hepatitis C virus. J Prev Med Hyg. 2015;54(2):83-6.
-
Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-a plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011;12(4):300-9.
-
Khubaib B, Saleem S, Idrees M, Afzal S, Wasim M. The genotype CC of IL-28B SNP rs12979860 is significantly associated with a sustained virological response in chronic HCV-infected Pakistani patients. J Dig Dis. 2015;16(5):293-8.